Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 69

  • 960 clinical trials
  • 390 recruiting
  • 346 conditions
  • 28 countries

Conditions in this area

346 conditions with trials, the busiest first

Breast cancer170Prostate cancer102Ovarian cancer90Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer42Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer19Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+322

Clinical trials in Reproductive system and breast disorders

960 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

960 clinical trials

Vaginal infection

Not recruiting

Study on the Effectiveness and Safety of BGY-1601-VT for Women with Acute Vaginal Infections, Including Bacterial Vaginosis and Yeast Infections

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Lactobacillus rhamnosus, strain LCR35, live
  • Sponsor:Nexbiome Therapeutics

Cervix carcinoma

Not recruiting

Study on the Effectiveness of HPV 9-Valent Vaccine in Women Undergoing LEEP for High-Grade Cervical Lesions or Early Cervical Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Water For Injection
  • Sponsor:Azienda Unita Sanitaria Locale Toscana Nord Ovest

Breast cancer stage IV

Not recruiting

Study of Eftilagimod Alpha and Paclitaxel in Patients with HER2-Negative/Low Metastatic Breast Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Eftilagimod Alfa
  • Sponsor:Immutep

HER2 positive breast cancer

Not recruiting

Study of Ipatasertib with Trastuzumab and Pertuzumab for Patients with Advanced HER2-Positive Breast Cancer and PIK3CA Mutation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ipatasertib
  • Sponsor:Solti Group

Infertility

Not recruiting

Study on Vaginal Progesterone for Improving Live Birth Rates in Women with Infertility Undergoing Frozen/Thawed IVF Natural Cycles

Registered drugNo placebo
Countries:IcelandIceland
  • Participants:18–64 years
  • Substances:Progesterone
  • Sponsor:Vaestra Goetalandsregionen

Breast cancer female

Not recruiting

Study on Infertility Risk from Chemotherapy in Young Breast Cancer Patients Using Follitropin Beta and Follitropin Alfa for Egg/Embryo Preservation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Follitropin Alfa
  • Sponsor:Centre Oscar Lambret

Breast cancer

Not recruiting

Comparison of estriol, prasterone and estriol with lactobacillus for vulvovaginal atrophy in breast cancer patients on endocrine therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Estriol
  • Sponsor:Universitair Ziekenhuis Gent

Prostate cancer

Not recruiting

Study on Prostate Cancer Treatment: Comparing Goserelin Acetate, Leuprorelin Acetate, Degarelix, and Apalutamide in Patients with Biochemical Progression After Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Ziekenhuis Aan De Stroom

Endometrial cancer+5

Not recruiting

A Phase 1/2a Study of BNT142 Safety and Early Effectiveness in Patients with Advanced Solid Tumors Expressing CLDN6 Protein

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:BioNTech SE

Gastric cancer+5

Not recruiting

Study on Aspirin's Effect on Recurrence and Survival in Patients with Non-Metastatic Breast, Colon, Rectal, Stomach, Esophageal, and Prostate Cancer

Registered drug
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:University College London

Triple negative breast cancer

Not recruiting

Study of Capivasertib and Paclitaxel for Patients with Advanced or Metastatic Triple-Negative Breast Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:AstraZeneca AB

Ovarian cancer recurrent

Not recruiting

Study on ADP-A2M4CD8 and Nivolumab for Patients with Recurrent Ovarian Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:USWM Ct LLC

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab76 clinical trialsLetrozole74 clinical trialsFulvestrant59 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane47 clinical trialsAnastrozole45 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.